Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03543358 · ClinicalTrials.gov registry record · Phase 2
A Long-Term Study of Rovalpituzumab Tesirine
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03543358 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 3 participants.
The verdict
NCT03543358, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this long-term, extension study is to provide ongoing safety and efficacy follow-up of subjects who participated in a rovalpituzumab tesirine study that has completed the primary analysis and that is closing.
Interventions
- DRUG rovalpituzumab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2019-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03543358
The ClinicalTrials.gov registry entry for NCT03543358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rovalpituzumab tesirine is the first listed.
NCT03543358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03543358 about?
NCT03543358 is a clinical study titled "A Long-Term Study of Rovalpituzumab Tesirine". The purpose of this long-term, extension study is to provide ongoing safety and efficacy follow-up of subjects who participated in a rovalpituzumab tesirine study that has completed the primary analysis and that is closing.
What is the current status of trial NCT03543358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2018-09-10. Estimated completion is 2019-11-26.
What interventions are being tested in trial NCT03543358?
The interventions under investigation include: rovalpituzumab tesirine (DRUG).
Who is sponsoring clinical trial NCT03543358?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.